億通科技(300211.SZ)一季度預盈125萬元–160萬元
格隆匯3月9日丨億通科技(300211.SZ)公佈,預計2020年度第一季度歸屬於上市公司股東的淨利潤125萬元–160萬元,同比增長1.63%-30.09%。
報告期內廣電行業市場價格競爭較為激烈,同時受疫情的影響,有線電視網絡傳輸設備市場銷售量下降,實現收入、毛利比去年同期有所下降;智能化工程受項目實施進度的影響,1-3月份公司智能化監控工程業務總體實現收入比去年同期有所下降。公司使用閒置自有資金進行現金管理,提高資金使用率,存款利息收益比去年同期增加。報告期間內,公司2020年1-3月份實現淨利潤比去年同期增加。
2020年第一季度非經常性損益對淨利潤的影響額預計為56萬元左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.